Are Wall Street Analysts Bullish on DaVita Stock?

Headquartered in Denver, Colorado, DaVita Inc. (DVA) is a leading provider of dialysis services for patients with chronic kidney failure, or end-stage renal disease (ESRD) in the U.S. With a market cap of $13.2 billion, the company’s other ancillary services and strategic initiatives segment encompasses international dialysis services, pharmacy and infusion therapy, disease management, vascular access, ESRD clinical research, and physician services.

Shares of the kidney specialist have surpassed the broader market over the past year. While DVA stock has surged 44.1% over this time frame, the S&P 500 Index ($SPX) has rallied by 26.1%. In 2024 alone, the stock rose 43.5%, compared to SPX’s 16.5% return on a YTD basis.